CHAVI-ID are two consortiums established by NIAID to undertake the immunologic research required to tackle the major scientific obstacles in the development of an effective HIV vaccine. The two seven-year awards were made in 2012, one to Duke University and a second to The Scripps Research Institute.
Main Areas of Focus
- To determine the viral and immunological events and host genetic factors associated with HIV transmission, infection and (partial) containment of virus replication
- To develop novel HIV-1 vectors, immunogens and adjuvants that suppress viral replication and elicit persistent mucosal and/or systemic immune responses
- To use SIV infection in primates as a model for HIV infection in humans and determine the factors that lead to mucosal protection from SIV in primates
- To test novel HIV-1 vaccine candidates in phase I clinical trials